US major Boston Scientific Corporation (NYSE: BSX) has officially launched its Vercisie Genius, an implantable deep brain stimulation (DBS) system, at the 7th CIIE. This move is set to enhance the treatment options available to China’s growing Parkinson’s disease (PD) population.
Parkinson’s Disease and Deep Brain Stimulation Therapy
Parkinson’s disease (PD), a neurodegenerative disorder predominantly affecting middle-aged and elderly individuals, is found in 1.7% of people aged 65 and above in China. The patient population is expected to reach 5 million by 2030, nearly half of the global PD cases. Currently, there is no cure for the disease, and symptoms are typically managed with medication, which can have side effects such as involuntary movement and movement fluctuations. As the condition progresses, the effectiveness of treatment may decline, making DBS therapy an effective alternative. The Vercisie Genius DBS system is designed to adjust treatment methods based on the progression of Parkinson’s disease in patients, meeting their specific needs for an extended period, with a super-long lifespan of up to 25 years. The product’s unique directional electrode design assists doctors in accurately stimulating target areas, avoiding regions with side effects, and reducing symptoms such as tremors, bradykinesia, and stiffness, thereby improving the motor function of PD patients. The Vercisie Genius has previously been approved for listing in markets including Europe and the United States.- Flcube.com
